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ABSTRACT
Background: The association of proteinuria and reduced estimated glomerular filtration rate (eGFR) with cognition needs more
clarification. We cross-sectionally examined whether proteinuria and reduced eGFR, even in moderate stages, were
independently associated with lower cognition in a community-based sample of elderly men.
Methods: Our cohort initially comprised 1,094 men aged 40–79 years from a random sample from Shiga, Japan in 2006–2008.
Of 853 men who returned for the follow-up examination (2009–2014), we analyzed 561 who were ≥65 years, free of stroke, and
completed the Cognitive Abilities Screening Instrument (CASI) at follow-up (higher CASI scores [range 0 to 100] indicate
better cognition). Proteinuria was assessed via dipstick. eGFR was calculated according to the Chronic Kidney Disease
Epidemiology Collaboration Equation. Participants were divided into three groups either by eGFR (≥60, 59–40, and <40mL=
min=1.73m2) or by proteinuria (no, trace, and positive), considered normal, moderate, and advanced, respectively. Using linear
regression, we computed mean CASI score, with simultaneous adjustment for proteinuria and eGFR in addition to other
potential confounders.
Results: Significant trends of lower cognition were observed across the groups of worse proteinuria and lower eGFR
independently: multivariable-adjusted mean CASI scores were 90.1, 89.3, and 88.4 for proteinuria (Ptrend = 0.029), and 90.0,
88.5, and 88.5 for eGFR (Ptrend = 0.015) in mutual-adjustment model.
Conclusions: Proteinuria and reduced eGFR, even in their moderate stages, were independently associated with lower cognition
in a community-based sample of elderly men. The results suggest the importance of proteinuria and low eGFR for early
detection and prevention of cognitive decline.
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INTRODUCTION
Early identification of modifiable risk factors for cognitive
decline and dementia is an important public health issue because
of the global burden of dementia and aging populations
worldwide. Chronic kidney disease (CKD), commonly defined
based on the presence of albuminuria=proteinuria and=or reduced
estimated glomerular filtration rate (eGFR), is considered a
potential risk factor for cognitive decline and dementia.1 The
kidneys and the brain are both susceptible to vascular damage
owing to their similarity in anatomic and hemodynamic features,
which may explain, in part, the CKD-cognition relationship.
However, existing literature remains limited as to whether both
proteinuria and eGFR are associated with cognitive impairment.





For example, in a recent meta-analysis of population-based
studies, albuminuria=proteinuria was most consistently associated
with cognitive impairment, but the association of reduced eGFR
(defined as <60mL=min=1.73m2) was weak and inconsistent
within the study results.2 Other important but unsettled questions
include whether moderate stages of albuminuria=proteinuria or
reduced eGFR are independently associated with low cognition,
and whether individuals with coexisting proteinuria and low
eGFR have lower cognition than individuals with either condition
alone. These questions have important clinical implications in
early detection and prevention of cognitive impairment because
the presence of either proteinuria or low eGFR, even in their
moderate stages, may alert the clinician and the patient to be more
aware of the need to prevent further deterioration of cognitive
impairment.
The primary aim of this study was to examine the association
of proteinuria and eGFR with cognitive function, separately
and jointly, in a community-based sample of elderly men. We
hypothesized that the presence of proteinuria and=or lower eGFR
are statistically independently associated with lower cognition in
a dose-response manner in apparently healthy men. We also
investigated whether the coexistence of proteinuria and low eGFR




The Shiga Epidemiological Study of Subclinical Atherosclerosis
is a study of subclinical atherosclerosis and its determinants on
a sample of Japanese residents. Details of the methods of
enrollment have been reported previously.3,4 In brief, from 2006
through 2008, we randomly selected and invited 2,379 Japanese
men aged 40–79 years who were residents of Kusatsu City,
Shiga, based on the Basic Residents’ Register of the city, to
participate in our study. The city, located in central Japan, has an
industrial structure similar to the average of that in Japan.5 The
Register contains information on name, sex, birth date, and
address of residents.6 A total of 1,094 men agreed to participate in
the baseline exam (participation rate, 46%). From 2009 through
2014, all participants were invited to take part in a follow-up
exam, and 853 of them agreed.7 The study was carried out in
accordance with the Code of Ethics of the World Medical
Association (Declaration of Helsinki) and approved by the
institutional review board of Shiga University of Medical
Science. Written informed consent was obtained from all
participants. For the present study, using a priori criteria, we
excluded those aged <65 years (n = 218), with a history of stroke
(n = 36), and who did not complete the Cognitive Abilities
Screening Instrument (CASI) at the follow-up exam (n = 32). We
further excluded the participants with missing pertinent variables
(n = 6), leaving 561 men for the final analyses.
Measurements
Data on medical history, use of medications, smoking, alcohol
intake, and other lifestyle factors were collected from each par-
ticipant using a self-administered questionnaire. Trained techni-
cians confirmed the completed questionnaire with participants.
Details on ascertaining smoking habits were reported previously,5
and a similar method was used to determine drinking habits. Body
weight and height were measured while the participant was
wearing light clothing without shoes. Blood pressure was
measured using an automated sphygmomanometer (BP-8800;
Colin Medical Technology, Komaki, Japan). Two consecutive
measurements in the right arm of the seated participant, after
sitting quietly for 5 minutes, were taken; the mean of these two
measurements was used for analyses. Blood specimens were
obtained early in the clinic visit after a 12-hour fast and used for
laboratory testing, including lipids and glucose concentrations.
Serum creatinine was measured by the enzymatic method (Espa
CRE-liquid II; NIPRO, Osaka, Japan). Serum lipid concentrations
were determined at a single laboratory (Shiga Laboratory;
MEDIC, Shiga, Japan) that had been certified for standardized
lipid measurements according to the protocols of the United States
Centers for Disease Control and Prevention=Cholesterol Refer-
ence Method Laboratory Network.8 Low-density lipoprotein
(LDL) cholesterol concentrations were calculated using the
Friedewald equation (In the case of triglycerides concentration
>400mg=dL, we treated them as missing).9 Glycated hemoglobin
(HbA1c) was measured using latex agglutination inhibition assay
according to either the Japan Diabetes Society (JDS) protocol or
that of the National Glycohemoglobin Standardization Program
(NGSP).10 JDS values were converted to NGSP values using the
equation recommended by JDS10: NGSP value (%) = 1.02 × JDS
value (%) + 0.25. We administered the 6-item Kessler Psycho-
logical Distress Scale (K6),11 a commonly used tool for the
assessment of mood. The K6 scale ranges from 0 to 24, with
higher scores indicating the presence of a mood disorder,
including depression. The validity of the K6 for a Japanese
population is reported elsewhere.12
Cognitive function
Cognitive function was evaluated by participants’ performance
on CASI (Version J-1.0), a validated comprehensive measure of
intellectual function comprised of 25 questions.13 Performance
scores (CASI score) range from 0 to 100, with higher scores
indicating better cognitive function. CASI scores <74 correspond
to a score of <22 on Folstein’s Mini-Mental State Examination,
raising the possibility of dementia.14 Three raters (AF, NM, and
YS) independently determined the CASI score based on recorded
responses from participants. The intraclass correlation coefficient
across the raters was 0.977 based on recorded samples of 20
participants.
Assessment of proteinuria and eGFR
Proteinuria was assessed using dipstick (Uriace; Terumo, Tokyo,
Japan). For eGFR, we used the CKD Epidemiology Collaboration
(CKD-EPI) equation modified for the Japanese in the main
analysis. The equation is as below15,16:
eGFR ¼ 141  ðs-Cr=0:9Þð0:411Þ  0:993ðAgeÞ  0:813;
for those with s-Cr 0:9mg=dL ð79:6mol=LÞ
eGFR ¼ 141  ðs-Cr=0:9Þð1:209Þ  0:993ðAgeÞ  0:813;
for those with s-Cr >0:9mg=dL ð79:6 mol=LÞ;
where s-Cr stands for serum creatinine. We chose the CKD-EPI
equation over the Modification of Diet in Renal Disease
(MDRD)-based equations because of its superior accuracy,17,18
with less bias at GFR ≥60mL=min=1.73m2,19 and better
predictability of cardiovascular and other outcomes20 shown in
multiple populations, including Japanese ones,15,21 compared to
the latter. In a sensitivity analysis, we replaced the CKD-EPI
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Equations with the MDRD-based equation,22 which is used in
the 2018 clinical practice guidelines by the Japanese Society of
Nephrology (JSN),23 as formulated below:
eGFRcreat ½mL=min=1:73m2
¼ 194  s-Cr ½mg=dLð1:094Þ  Age ½yearð0:287Þ:
We defined low eGFR as eGFR <60mL=min=1.73m2,
proteinuria as trace or greater degree of proteinuria, and CKD
as either having low eGFR or proteinuria.
Statistical analysis
In the main analysis, we divided participants into categories
according to eGFR levels of ≥60, 59 to 40, and <40 [mL=min=
1.73m2], and proteinuria as absent (−), trace (±), and positive
(≥1+), operationally considering each category as normal,
moderate, and advanced stage, respectively. The eGFR cutoff
of <40mL=min=1.73m2 was chosen somewhat arbitrarily. At the
inception of the study we planned to use cutoff of <30mL=min=
1.73m2 as it defines advanced reduction of eGFR in some
guidelines23,24 and we had a concern that use of a higher eGFR
cutoff, such as 45, may introduce more variation in cognition
level relative to the group of people with eGFR <30. However,
owing to the fact that few participants (n = 2) had an eGFR <30
mL=min=1.73m2, we have elected to use 40mL=min=1.73m2
for the cutoff to balance between maintaining a reasonable
sample size versus observing enough effect of reduced eGFR
on cognition. Hypertension was defined as systolic=diastolic
blood pressure ≥140=90mmHg or medication use. Diabetes
mellitus was defined as fasting blood glucose ≥7.0mmol=L
(≥126mg=dL) or HbA1c (NGSP) ≥6.5% or medication use.
Dyslipidemia was defined as LDL cholesterol concentration
≥3.6mmol=L (140mg=dL),25 high-density lipoprotein (HDL)
cholesterol concentration <1.0mmol=L (40mg=dL), or dyslipi-
demia medication use.
Linear regression was used to obtain adjusted mean CASI
score treating explanatory categories (eGFR and proteinuria) as
nominal. For confirmation, we first examined whether the
presence of CKD was associated with lower CASI score in
reference to the absence of CKD after multivariable adjustment.
Second, we examined potential dose-response by inserting
categories of either proteinuria (no, trace, positive: nominal) or
eGFR (<40, 40–59, ≥60mL=min=1.73m2: nominal), separately
as an explanatory variable (single adjustment model). Third, we
simultaneously included the categories of proteinuria and eGFR
to examine the mutual independence in relationship to cognition
(mutual adjustment model). Finally, for the secondary aim, we
categorized participants into three groups based on the status
of low eGFR (<60mL=min=1.73m2) and proteinuria (trace or
more): “No CKD” represented having neither low eGFR nor
proteinuria, “isolated low eGFR or proteinuria” represented
having either low eGFR or proteinuria but not both, and “low
eGFR and proteinuria” represented having both conditions. Then
we compared adjusted CASI scores among the three groups.
P-values for trends were computed treating the categories as
ordinal. In post-hoc analysis, we further repeated the analysis
according to four nominal categories by separating isolated low
eGFR and isolated proteinuria considering that they may have
different pathophysiology from each other. We adjusted for the
following covariates throughout the models: age (years), highest
education year attained (years),26–28 drinking and smoking habits
(current=past=never), body mass index (kg=m2), hypertension
(yes=no), diabetes mellitus (yes=no), dyslipidemia (yes=no), and
hemoglobin concentration (g=dL). In a post-hoc sensitivity
analysis, we explored whether adding the K6 score to the model
affected the main results. In a separate post-hoc sensitivity
analysis, we replaced eGFR cutoff of 40 with 45mL=min=
1.73m2 and repeated an analysis parallel to the main one. Values
of P < 0.05 were considered significant, and all analyses were
two-tailed. SAS version 9.4 software (SAS Institute, Cary, NC,
USA) was used.
RESULTS
Of 561 participants, 270 men (48.1%) met the definition of CKD
either by isolated proteinuria or isolated low eGFR (n = 224) or
by the presence of both (n = 46). Table 1 shows characteristics of
participants according to proteinuria status (eTable 1 shows the
characteristics according to eGFR category). The mean values for
age, eGFR, and CASI score were 72.0 (standard deviation [SD],
4.4) years, 67.5 (SD, 19.1)mL=min=1.73m2, and 89.8 (SD, 5.9),
respectively. The number of participants who had no, trace, or
positive (≥1+) proteinuria was 343 (61.1%), 189 (33.7%), and 29
(5.2%), respectively. The number of participants who had eGFR
of ≥60, 59–40, and <40mL=min=1.73m2 were 463 (82.5%), 84
(15.0%), and 14 (2.5%), respectively (eTable 1). Two participants
had eGFR <30mL=min=1.73m2 either by the CKD-EPI equation
or the JSN equation, and only one reported receiving regular
dialysis. Those who were in a higher category of proteinuria
tended to be younger, have diabetes, and have lower eGFR and
lower CASI scores. Participants with CKD had a mean CASI
score of 89.1, which was 1.26 points lower than those without
CKD after multivariable adjustment (P < 0.01, eTable 2). The
magnitude of the difference was equivalent to more than a 3-year
difference in age (ie, CASI score of 0.38=age × 3 ≈ 1.26) in the
model.
Main analyses
Table 2 shows crude and adjusted mean CASI score according to
categories of proteinuria and eGFR. In single adjustment models,
a higher degree of proteinuria or lower eGFR had a significant
trend with lower CASI score in a dose-response fashion, after
controlling for potential confounders (P for trends were 0.011 and
0.006, respectively). The trends remained statistically significant
for both proteinuria and eGFR even after the mutual adjustment
(P for trends were 0.029 and 0.015, respectively) with slight
attenuations across each category of proteinuria or eGFR. Table 3
shows crude CASI score and characteristics according to three
groups: “no CKD” (n = 291, 51.9%), “isolated low eGFR or
proteinuria” (224, 39.9%), and “low eGFR and proteinuria” (46,
8.2%). Participants with “low eGFR and proteinuria” tended to be
older, obese, and have hypertension, diabetes, lower concen-
trations of HDL cholesterol and hemoglobin, and lower CASI
scores. Figure 1 shows that multivariable-adjusted mean CASI
score was high in the order of “No CKD” (adjusted mean CASI
score, 90.4; 95% confidence interval [CI], 89.8–91.0), “isolated
low eGFR or proteinuria” (89.4; 95% CI, 88.7–90.1), and “low
eGFR and proteinuria” (87.5; 95% CI, 86.0–89.1). The scores
of the three groups were significantly different from each other
(see Figure 1 legend). In post-hoc analysis separating isolated
proteinuria (n = 172) and isolated low eGFR (n = 52), crude
mean CASI score for each of two category was 89.9 and 88.7,
respectively. Multivariable-adjusted mean CASI score was high,
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(n = 343) (n = 189) (n = 29)
Age, years 72.0 (4.4) 72.2 71.8 70.2 0.03
Education, years 12.5 (2.4) 12.5 12.6 12.1 0.79
Body mass index, kg=m2 23.1 (2.9) 23.0 23.2 23.3 0.39
Systolic blood pressure, mmHg 133 (16.5) 133 132 136 0.66
LDL-cholesterol, micromol=L 3.03 (0.76) 3.05 3.02 2.89 0.36
mg=dLb 117 (29.2) 118 117 112
HDL-cholesterol, micromol=L 1.53 (0.43) 1.54 1.53 1.44 0.34
mg=dLb 59 (16.6) 60 59 56
HbA1c, NGSP, % 6.0 (0.9) 5.9 6.1 5.8 0.30
Smoking, %
current 16.6 15.2 17.5 27.6 0.26
past 63.8 63.8 67.2 41.4
never 19.6 21.0 15.3 31.0
Drinking, %
current 78.1 79.6 76.2 72.4 0.24c
past 5.7 5.8 5.3 6.9
never 16.2 14.6 18.5 20.7
Hypertension, % 62.4 60.6 63.0 79.3 0.11
Dyslipidemia, % 47.8 46.4 50.8 44.8 0.57
Diabetes mellitus, % 25.8 22.2 31.7 31.0 0.02
Hemoglobin, g=dL 14.4 (1.6) 14.4 14.3 14.4 0.39
K6 scaled 8.7 (3.0) 8.6 9.1 8.2 0.31
Serum creatinine, micromol=L 79.6 (18.6) 77.8 80.4 94.6 <0.01
mg=dLe 0.9 (0.2) 0.88 0.91 1.07
eGFR, mL=min=1.73m2 67.5 (19.1) 68.1 67.0 63.0 0.01
CASI score 89.8 (5.9) 90.1 89.3 88.2 0.05
BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; K6, 6-item Kessler Psychological Distress Scale; LDL, low-
density lipoprotein; NGSP, National Glycohemoglobin Standardization Program; CASI, the Cognitive Abilities Screening Instrument.
CASI score ranges from 0 to 100, with scores <74 raising the possibility of dementia; eGFR estimates were computed using serum creatinine concentration
according to the CKD Epidemiology Collaboration (CKD-EPI) Equation modified for the Japanese; Hypertension: defined as systolic=diastolic blood pressure
≥140=90mmHg or medication use; Diabetes mellitus: defined as fasting glucose ≥7.0mmol=L (126mg=dL) or HbA1c [NGSP] ≥6.5% or medication use;
Dyslipidemia: defined as LDL-cholesterol ≥3.6mmol=L (140mg=dL) or HDL-cholesterol <1.0mmol=L (40mg=dL) or medication use.
aP-values were computed using linear regression treating proteinuria category as ordinal for continuous variable, and by Mantel Haenzel test for linear trend.
bConversion unit for serum low-density cholesterol and high-density cholesterol from mmol=L to mg=dL is 38.61.
cCategories of drinking were collapsed to current vs non-current because of too few past drinkers.
dFour participants had missing scales.
eConversion unit for serum creatinine from micromol=L to mg=dL is 0.0113.
Table 2. Crude and multivariable-adjusted mean CASI score according to proteinuria and/or eGFR category in men aged ;65 years who




Single adjustmenta Mutual adjustmentb
score (95% CI) trend P score (95% CI) trend P
Proteinuria no 343 90.1 (5.4) 90.2 (89.6, 90.7) 90.1 (89.6, 90.7)
trace 189 89.3 (6.7) 89.2 (88.5, 90.0) 0.011 89.3 (88.5, 90.0) 0.029
≥(1+) 29 88.2 (6.7) 88.1 (86.2, 90.1)+ 88.4 (86.4, 90.4)
eGFRc, mL=min=1.73m2 ≥60 463 90.2 (5.5) 90.1 (89.6, 90.5) 90.0 (89.5, 90.5)
59–40 84 88.0 (7.1) 88.4 (87.2, 89.5)+ 0.006 88.5 (87.3, 89.6)+ 0.015
<40 14 85.6 (8.0) 88.0 (85.1, 90.8) 88.5 (85.6, 91.4)
CASI, Cognitive Abilities Screening Instrument; CI, confidence interval; eGFR, estimated glomerular filtration rate; SD, standard deviation.
CASI is scored 0–100, with scores <74 raising the possibility of dementia; Hypertension: defined as systolic=diastolic blood pressure ≥140=90mmHg or
medication use; Diabetes mellitus: defined as fasting glucose ≥7.0mmol=L (126mg=dL) or HbA1c [NGSP] ≥6.5% or medication use; Dyslipidemia: defined as
LDL-cholesterol ≥3.6mmol=L (140mg=dL) or HDL-cholesterol <1.0mmol=L (40mg=dL) or medication use. In all adjustment, the following covariates were
included: age (years), highest education attained (years), drinking=smoking habit (current=past=never), body mass index (kg=m2), hypertension (yes=no),
diabetes mellitus (yes=no), dyslipidemia (yes=no) and hemoglobin (g=dL).
aIn single adjustment model, either proteinuria (no=trace=≥1+) or eGFR-category (<40=40–59=≥60mL=min=1.73m2) was included.
bIn mutual adjustment model, both proteinuria and eGFR were included.
cEstimates were computed using serum creatinine concentration according to the CKD Epidemiology Collaboration (CKD-EPI) Equation modified for the
Japanese.
+Statistically significant (P < 0.05) as compared to normal category (either no proteinuria or eGFR ≥60mL=min=1.73m2).
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by point estimate, in the order of “no CKD”, “isolated pro-
teinuria”, “isolated low eGFR”, and “low eGFR and proteinuria.”
However, there was no statistical difference in the adjusted mean
CASI score between isolated proteinuria and isolated eGFR
(eTable 3).
Sensitivity analyses
Replacing the CKD-EPI equation-based eGFR with that by the
JSN equation resulted in fewer participants categorized as eGFR
≥60mL=min=1.73m2 (n = 463 by the CKD-EPI equation versus
404 by the JSN equation). Otherwise, however, the results were
similar to the main ones (eTable 4). Excluding those participants
with eGFR ≤30mL=min=1.73m2 (n = 2) or use of model
including K6 scale did not change the findings of the main
analyses materially (data not shown). Use of eGFR cutoff of <45
instead of <40mL=min=1.73m2 resulted in attenuation of graded
relationship between CASI score and eGFR category to no
significance (P trend = 0.069 in mutual adjustment model,
eTable 5). The alternatively defined moderate eGFR category
(45–59mL=min=1.73m2), however, remained to be associated
with significantly lower adjusted CASI score compared to normal
eGFR category.
DISCUSSION
In this population-based, cross-sectional study of apparently
healthy, elderly Japanese men, we found that proteinuria and
reduced eGFR were independently associated with lower
cognitive function in a graded manner in single adjustment
models. The association was independent of conventional
vascular risk factors and hemoglobin concentrations. To our
knowledge, the present study is the first community-based study
that showed dose-response relationships with both proteinuria
and low eGFR in relation to cognitive function, although the
graded relation with low eGFR was somewhat sensitive to cutoff
value. Furthermore, the overall trend remained similar and
statistically significant after mutual adjustment for proteinuria
and low eGFR.
Identifying risk factors for cognitive decline=dementia is of
utmost importance given the rapidly aging populations globally.
Table 3. Crude CASI score and characteristics according to presence or absence of low eGFR and proteinuria in men aged ;65 years







N 291 224 46
Age, years 72.0 71.7 73.7 0.02
Education, years 12.4 12.6 12.1 0.42
Body mass index, kg=m2 23.0 23.1 24.3 0.01
Systolic BP, mmHg 133 132 135 0.57
LDL-cholesterol, micromol=L 3.05 3.04 2.87 0.30
mg=dLb 118 118 111
HDL-cholesterol, micromol=L 1.56 1.52 1.40 0.03
mg=dLb 60 59 54
HbA1c, NGSP, % 5.9 6.0 6.1 0.26
Smoking, %
current 15.5 19.2 10.9 0.64
past 64.6 61.6 69.6
never 19.9 19.2 19.6
Drinking, %
current 79.7 77.2 71.7 0.72
past 5.8 5.4 6.5
never 14.4 17.4 21.7
Hypertension, % 59.8 60.7 87.0 <0.01
Dyslipidemia, % 45.0 49.6 56.5 0.11
Diabetes mellitus, % 22.3 27.7 39.1 0.04
Hemoglobin, g=dL 14.5 14.3 13.9 0.04
K6 scalec 8.6 8.7 9.6 0.10
Serum creatinine, micromol=L 73.4 80.4 112.3 <0.01
mg=dLd 0.83 0.91 1.27
eGFR, mL=min=1.73m2 71.1 66.8 48.1 <0.01
CASI score 90.4 89.6 86.5 <0.01
BMI, body mass index; CASI, Cognitive Abilities Screening Instrument; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; K6, 6-item
Kessler Psychological Distress Scale; LDL, low-density lipoprotein; NGSP, National Glycohemoglobin Standardization Program.
CASI scores ranges from 0 to 100, with scores <74 raising the possibility of dementia; Estimates were computed using serum creatinine concentration according
to the CKD Epidemiology Collaboration (CKD-EPI) Equation modified for the Japanese; Hypertension: defined as systolic=diastolic blood pressure ≥140=
90mmHg or medication use; Diabetes mellitus: defined as fasting glucose ≥7.0mmol=L (126mg=dL) or HbA1c [NGSP] ≥6.5% or medication use;
Dyslipidemia: defined as LDL-cholesterol ≥3.6mmol=L (140mg=dL) or HDL-cholesterol <1.0mmol=L (40mg=dL) or medication use. Values are crude mean
unless otherwise specified. Low eGFR was defined as eGFR <60mL=min=1.73m2. Proteinuria was defined as trace or higher degree of proteinuria.
aP-values were computed using linear regression treating three categories (“No CKD”, “Isolated low eGFR or proteinuria”, and “Low eGFR and proteinuria”) as
ordinal.
bConversion unit for serum low-density cholesterol and high-density cholesterol from mmol=L to mg=dL is 38.61.
cFour participants had missing scales.
dConversion unit for serum creatinine from micromol=L to mg=dL is 0.0113.
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However, the relationship of proteinuria and=or reduced eGFR
with cognitive function needs more clarification. A meta-analysis
published in 2012 showed elevated odds of cognitive decline in
individuals with CKD than those without CKD,1 but only one29
of 10 studies assessed in the meta-analysis included proteinuria
(albuminuria) in their definitions of CKD. A more recent meta-
analysis evaluated the associations of cognitive impairment with
proteinuria=albuminuria and eGFR separately. It concluded that
proteinuria=albuminuria was most consistently associated with
cognitive impairment, consistent with other meta-analysis,30 but
the association of reduced GFR (defined as <60mL=min=1.73
m2) was weak and inconsistent.2 Furthermore, many previous
studies used only dichotomized category of CKD (presence=
absence), and a dose-response relationship of eGFR or proteinuria
with cognition was not consistently documented.31 For example,
the Hisayama Study, one of the best-known prospective cohort
studies in Japan, recently reported a dose-response relationship
between baseline albuminuria and risk of dementia (all-cause,
Alzheimer, and vascular type).32 However, they observed a
marginal association of reduced eGFR, defined as <60mL=min=
1.73m2 using a similar method to ours, only with vascular
dementia but not with Alzheimer dementia, and they did not
assess dose-response relation of eGFR.32 Other longitudinal
studies, such as the Northern Manhattan Study,33 showed a
significant relation of reduced eGFR and cognitive decline,
whereas others reported no clear relationship between them.34
In our study, we observed a significant inverse graded trend of
proteinuria, and a significantly lower CASI score in participants
with an eGFR of 40–59, or 45–59, mL=min=1.73m2 as compared
to those with normal eGFR (≥60mL=min=1.73m2). These
findings have an important implication, as they suggest that
the presence of either moderate stage of proteinuria or that of
low eGFR should alert a clinician and a patient of the potential
presence of impaired cognition that may require intervention to
prevent further deterioration. Another important finding of the
study is that participants with coexisting proteinuria and low
eGFR had the lowest CASI score followed by those with isolated
proteinuria or low eGFR compared to participants without CKD.
This finding is expected because such coexistence often indicates
more advanced renal dysfunction. However, only a few epide-
miologic studies, to our knowledge, have evaluated a joint
association of proteinuria and reduced eGFR with cognition=
dementia.32 The finding suggests that the coexistence of
proteinuria and reduced eGFR indicates elevated risk of dementia
even in apparently healthy men with no history of stroke.
The mechanism linking proteinuria or reduced GFR and
cognitive impairment is not well understood. Proteinuria and low
eGFR are robust predictors for vascular disease and all-cause
death.35 Many studies reported a close relationship between CKD
and subclinical brain pathologies, including small vessel
diseases.31,36 This is not surprising given the common anatomic
and vaso-regulatory features of the brain and the kidneys, low-
resistant end organs that are susceptible to vascular damage, as
both organs receive high-volume blood flow.31 Individuals with
proteinuria or reduced GFR are likely to have subclinical small
vessel disease in the brain,36–38 which is believed to play a causal
role in cognitive impairment and dementia.39 Another potential
explanation would be shared risk factors between CKD and
Figure 1. Multivariable-adjusted mean CASI score according to the presence or absence of low eGFR and proteinuria in men
aged ;65 years who were free of stroke (N = 561, 2009–2014, Shiga, Japan). Each bar and whiskers represent
multivariable-adjusted mean CASI score and 95% confidence intervals. The set of adjusting covariates was same as in
the main analyses: age (years), highest education attained (years), drinking/smoking habit (current/past/never), body
mass index (kg/m2), hypertension (yes/no), diabetes mellitus (yes/no), dyslipidemia (yes/no), and hemoglobin (g/dL).
Adjusted mean CASI scores in the three groups were statistically significantly different from each other: P-values for
pairwise comparison were 0.04 between “no CKD” and “isolated eGFR or proteinuria”, <0.01 between “no CKD” and
“low eGFR and proteinuria”, and 0.03 between “isolated eGFR or proteinuria” and “low eGFR and proteinuria”.
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impaired cognition such as hypertension, diabetes mellitus, and
smoking.40,41
There are other potential mechanisms that may explain the
association at least in part. For example, anemia and depression
are common in patients with CKD, and may lower cognition.
However, we adjusted for hemoglobin concentrations in our main
models, and adding the K6 scale to the models did not materially
alter our results. Other conditions that may be common in CKD
patients and associated with low cognition include polypharmacy
(with or without hypnotics) and subclinical=undiagnosed hypo-
thyroidism.42 However, we did not assess those conditions, so we
cannot rule out potential confounding by them.
Our sample was randomly selected from apparently healthy
community-based elderly men from a city in Japan, and approx-
imately one third and one quarter of the studied participants
had hypertension and diabetes, respectively. Probable etiologies
of proteinuria or low eGFR in our sample, therefore, include
hypertension and diabetes, the main causes of CKD in high- to
middle-income countries worldwide,43 rather than less common
pathologies, such as chronic glomerular nephritis. Hence, our
results may not be applicable to a group of patients with
uncommon etiologies of proteinuria or reduced eGFR, although
we do not have formal clinical diagnoses in our participants
categorized to CKD.
We used a dipstick for assessment of proteinuria, which is less
accurate than other measures, such as urine albumin-to-creatinine
ratio (ACR) or quantified measure of proteinuria via 24-hour
urine collection. However, at a population level, dipstick-assessed
proteinuria was shown to have a graded relationship with
cardiovascular and all-cause mortalities comparable to ACR,35
suggesting that dipstick assessment is reasonably reliable for the
assessment of proteinuria in epidemiological studies.
The observed difference in CASI score appears to be small.
However, given our population-based sample being relatively
healthy, in which overall cognition level was preserved and only
two participants had eGFR ≤30mL=min=1.73m2, it should not
minimize the impact of proteinuria or low eGFR for early
identification of cognitive impairment. The observed graded
relationship with eGFR was attenuated in the sensitivity analysis
that replaced the eGFR cutoff of 40 with 45mL=min=1.73m2.
This attenuation is not surprising because use of higher eGFR
cutoff in categorizing the lowest eGFR group may introduce more
variation in cognitive level, especially when considering a small
number of participants in our sample who had a low eGFR. The
replacement with cutoff of 45, however, did not change our
finding that the moderately low eGFR (defined as either 59 to 40,
or 59 to 45mL=min=1.73m2) group had a significantly lower
adjusted mean CASI score compared to normal eGFR group.
Moreover, the replacement had no effect on the observed
independent relationship between proteinuria and cognition
(Table 2 and eTable 5). Further studies with more participants
having reduced eGFR are needed to obtain more stable estimates.
Certain limitations should be considered when interpreting
our findings. First, the results may not be applicable to women
because we studied only men. Second, we evaluated proteinuria
and eGFR only once on the assumption that the observed results
persisted, which perhaps led to more misclassifications in our
categorizations of proteinuria and eGFR. However, it may bias
our inference toward the null, underestimating the true associa-
tion, if such misclassifications were random. Third, our outcome
was a one-time measure of cognitive function, not a decline of it,
which is a criterion of the common definition of dementia.
However, studies show that cognitive function assessed at one
point time predicts future dementia.44–46 Finally, given the
observational and cross-sectional nature of the study, we were
unable to prove the direction of temporality of the observed
association between exposure (kidney function) and cognition.
Strengths of our study include the population-based enrollment,
use of a standardized protocol in evaluating outcomes and
exposures, and adjustment for covariates.
Conclusions
We found that proteinuria and reduced eGFR were independently
associated with lower cognitive function in a graded fashion,
and that the coexistence of these conditions was associated with
the lowest cognitive function compared to other groups in a
community-based sample of elderly men. The results underscore
the importance of proteinuria and reduced eGFR for early
detection and prevention of cognitive decline in a general
population of elderly men.
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